Studies of bone morphogenetic protein-based surgical repair

Advanced Drug Delivery Reviews

Volumn 64, Issue 12, 2012, Pages 1277-1291

  Lo, Kevin W H ^a   Ulery, Bret D ^a   Ashe, Keshia M ^a,b   Laurencin, Cato T ^a,b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Bone fracture; Bone tissue engineering; Drug delivery; Oral surgery; Regenerative medicine; RhBMPs; Spinal surgery

Indexed keywords

BONE FRACTURE; BONE TISSUE ENGINEERING; REGENERATIVE MEDICINE; RHBMPS; SPINAL SURGERY;

BONE; DRUG DELIVERY; HYDROGELS; PROTEINS; TISSUE ENGINEERING;

SURGERY;

ALGINIC ACID; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE DIBASIC; CHITOSAN; COLLAGEN SPONGE; FIBRIN; GELATIN; HYALURONIC ACID; HYDROXYAPATITE; POLYCAPROLACTONE; POLYDIOXANONE; POLYETHERETHERKETONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; RECOMBINANT BONE MORPHOGENETIC PROTEIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT GROWTH FACTOR; RECOMBINANT OSTEOGENIC PROTEIN 1; SILK FIBROIN; TISSUE SCAFFOLD; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BIODEGRADABILITY; BONE ALLOGRAFT; BONE DEVELOPMENT; BONE REGENERATION; BONE REMODELING; CLAVICLE FRACTURE; COST CONTROL; DRUG UTILIZATION; FEMUR FRACTURE; FOOD AND DRUG ADMINISTRATION; FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; FRACTURE TREATMENT; HUMAN; HUMERUS FRACTURE; HYDROGEL; MAXILLOFACIAL SURGERY; MEDICAL RESEARCH; MUSCULOSKELETAL DISEASE; NONHUMAN; OFF LABEL DRUG USE; ORAL SURGERY; ORTHOPEDIC SURGERY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIUS FRACTURE; REVIEW; SPINE FUSION; SPINE SURGERY; TIBIA FRACTURE; TISSUE ENGINEERING; ULNA FRACTURE; UNITED STATES;

ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; BONE REGENERATION; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; HUMANS; RECOMBINANT PROTEINS; TISSUE ENGINEERING; TISSUE SCAFFOLDS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865291114     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.03.014     Document Type: Review

References (267)

1. U.S. Market for Fracture Fixation Products, 2011 Analysis 14 September 2011, Medtech INsight, Life Science Intelligence, Inc, Hungtington Beach, CA, http://www.lifescienceintelligence.com/market-reports-page.php?id=A326.
2. Garbuz D.S., Masri B.A., Czitrom A.A. Biology of allografting. Orthop. Clin. North Am. 1998, 29:199-204.
3. Summers B.N., Eisenstein S.M. Donor site pain from the ilium. A complication of lumbar spine fusion. J. Bone Joint Surg. Br. 1989, 71:677-680.
4. Gazdag A.R., Lane J.M., Glaser D., Forster R.A. Alternatives to autogenous bone graft: efficacy and indications. J. Am. Acad. Orthop. Surg. 1995, 3:1-8.
5. Pollock R., Alcelik I., Bhatia C., Chuter G., Lingutla K., Budithi C., Krishna M. Donor site morbidity following iliac crest bone harvesting for cervical fusion: a comparison between minimally invasive and open techniques. Eur. Spine J. 2008, 17:845-852.
6. Conway J.D. Autograft and nonunions: morbidity with intramedullary bone graft versus iliac crest bone graft. Orthop. Clin. North Am. 2010, 41:75-84. (table of contents).
7. Feighan J.E., Davy D., Prewett A.B., Stevenson S. Induction of bone by a demineralized bone matrix gel: a study in a rat femoral defect model. J. Orthop. Res. 1995, 13:881-891.
8. Hartigan B.J., Cohen M.S. Use of bone graft substitutes and bioactive materials in treatment of distal radius fractures. Hand Clin. 2005, 21:449-454.
9. Pacaccio D.J., Stern S.F. Demineralized bone matrix: basic science and clinical applications. Clin. Podiatr. Med. Surg. 2005, 22:599-606. (vii).
10. Aichelmann-Reidy M.E., Yukna R.A. Bone replacement grafts. The bone substitutes. Dent. Clin. North Am. 1998, 42:491-503.
11. Friedlaender G.E. Immune responses to osteochondral allografts. Current knowledge and future directions. Clin. Orthop. Relat. Res. 1983, 58-68.
12. Bawer T.W., Muschler G.F. Bone graft materials. An overview of the basic science. Clin. Orthop. Relat. Res. 2000, 371:10-27.
13. Laurencin C.T., Attawia M.A., Elgendy H.E., Herbert K.M. Tissue engineered bone-regeneration using degradable polymers: the formation of mineralized matrices. Bone 1996, 19:93S-99S.
14. Laurencin C.T., Ambrosio A.M., Borden M.D., Cooper J.A. Tissue engineering: orthopedic applications. Annu. Rev. Biomed. Eng. 1999, 1:19-46.
15. Borden M., El-Amin S.F., Attawia M., Laurencin C.T. Structural and human cellular assessment of a novel microsphere-based tissue engineered scaffold for bone repair. Biomaterials 2003, 24:597-609.
16. Laurencin C.T., Khan Y., Kofron M., El-Amin S., Botchwey E., Yu X., Cooper J.A. The ABJS Nicolas Andry Award: tissue engineering of bone and ligament: a 15-year perspective. Clin. Orthop. Relat. Res. 2006, 447:221-236.
17. Khan Y., Yaszemski M.J., Mikos A.G., Laurencin C.T. Tissue engineering of bone: material and matrix considerations. J. Bone Joint Surg. Am. 2008, 90(Suppl. 1):36-42.
18. Laurencin C., Khan Y., El-Amin S.F. Bone graft substitutes. Expert Rev. Med. Devices 2006, 3:49-57.
19. Boden S.D. Bioactive factors for bone tissue engineering. Clin. Orthop. Relat. Res. 1999, S84-S94.
20. Heldin C.H., Miyazono K., ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471.
21. Lieberman J.R., Daluiski A., Einhorn T.A. The role of growth factors in the repair of bone. Biology and clinical applications. J. Bone Joint Surg. Am. 2002, 84-A:1032-1044.
22. Bessa P.C., Casal M., Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J. Tissue Eng. Regen. Med. 2008, 2:1-13.
23. Kanayama M., Hashimoto T., Shigenobu K., Yamane S., Bauer T.W., Togawa D. A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine (Phila Pa 1976) 2006, 31:1067-1074.
24. Schmidmaier G., Schwabe P., Wildemann B., Haas N.P. Use of bone morphogenetic proteins for treatment of non-unions and future perspectives. Injury 2007, 38:S35-S41.
25. Garrison K.R., Donell S., Ryder J., Shemilt I., Mugford M., Harvey I., Song F. Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review. Health Technol. Assess. 2007, 11:1-150. (iii-iv).
26. Termaat M.F., Den Boer F.C., Bakker F.C., Patka P., Haarman H.J. Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects. J. Bone Joint Surg. Am. 2005, 87:1367-1378.
27. Dean D.B., Watson J.T., Moed B.R., Zhang Z. Role of bone morphogenetic proteins and their antagonists in healing of bone fracture. Front. Biosci. 2009, 1:2878-2888.
28. Kanakaris N.K., et al. Application of BMP-7 to tibial non-unions: a 3-year multicenter experience. Injury 2008, 39(Suppl. 2):S83-S90.
29. Park J.B. Use of bone morphogenetic proteins in sinus augmentation procedure. J. Craniofac. Surg. 2009, 20:1501-1503.
30. Kanakaris N.K., Lasanianos N., Calori G.M., Verdonk R., Blokhuis T.J., Cherubino P., De Biase P., Giannoudis P.V. Application of bone morphogenetic proteins to femoral non-unions: a 4-year multicentre experience. Injury 2009, 40(Suppl. 3):S54-S61.
31. Moghaddam A., Elleser C., Biglari B., Wentzensen A., Zimmermann G. Clinical application of BMP 7 in long bone non-unions. Arch. Orthop. Trauma Surg. 2010, 130:71-76.
32. O'hEireamhoin S., Quinlan J.F., Rourke K.O. The use of bone morphogenetic protein 7 in fracture non-unions. Orthop. Surg. 2011, 3:40-44.
33. Spagnoli D.B., Marx R.E. Dental implants and the use of rhBMP-2. Oral Maxillofac Surg. Clin. North Am. 2011, 23:347-361.
34. Urist M.R. Bone: formation by autoinduction. Science 1965, 150:893-899.
35. Abe E. Function of BMPs and BMP antagonists in adult bone. Ann. N. Y. Acad. Sci. 2006, 1068:41-53.
36. El-Amin S.F., Hogan M.V., Allen A.A., Hinds J., Laurencin C.T. The indications and use of bone morphogenetic proteins in foot, ankle, and tibia surgery. Foot Ankle Clin. 2010, 15:543-551.
37. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., Hewick R.M., Wang E.A. Novel regulators of bone formation: molecular clones and activities. Science 1988, 242:1528-1534.
38. Wang E.A., et al. Recombinant human bone morphogenetic protein induces bone formation. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:2220-2224.
39. Sampath T.K., et al. Recombinant human osteogenic protein-1 (hOP-1) induces new bone formation in vivo with a specific activity comparable with natural bovine osteogenic protein and stimulates osteoblast proliferation and differentiation in vitro. J. Biol. Chem. 1992, 267:20352-20362.
40. Israel D.I., Nove J., Kerns K.M., Moutsatsos I.K., Kaufman R.J. Expression and characterization of bone morphogenetic protein-2 in Chinese hamster ovary cells. Growth Factors 1992, 7:139-150.
41. Hillger F., Herr G., Rudolph R., Schwarz E. Biophysical comparison of BMP-2, ProBMP-2, and the free pro-peptide reveals stabilization of the pro-peptide by the mature growth factor. J. Biol. Chem. 2005, 280:14974-14980.
42. Bostrom M.P., Camacho N.P. Potential role of bone morphogenetic proteins in fracture healing. Clin. Orthop. Relat. Res. 1998, S274-S282.
43. Laurencin C.T., Attawia M.A., Lu L.Q., Borden M.D., Lu H.H., Gorum W.J., Lieberman J.R. Poly(lactide-co-glycolide)/hydroxyapatite delivery of BMP-2-producing cells: a regional gene therapy approach to bone regeneration. Biomaterials 2001, 22:1271-1277.
44. Reddi A.H. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat. Biotechnol. 1998, 16:247-252.
45. Lo K.W., Ulery B.D., Deng M., Ashe K.M., Laurencin C.T. Current patents on osteoinductive molecules for bone tissue engineering. Recent Pat. Biomed. Eng. 2011, 4:168-184.
46. Poynton A.R., Lane J.M. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 2002, 27:S40-S48.
47. Seeherman H.J., Bouxsein M., Kim H., Li R., Li X.J., Aiolova M., Wozney J.M. Recombinant human bone morphogenetic protein-2 delivered in an injectable calcium phosphate paste accelerates osteotomy-site healing in a nonhuman primate model. J. Bone Joint Surg. Am. 2004, 86-A:1961-1972.
48. Seeherman H., Wozney J.M. Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev. 2005, 16:329-345.
49. Nakashima M., Reddi A.H. The application of bone morphogenetic proteins to dental tissue engineering. Nat. Biotechnol. 2003, 21:1025-1032.
50. White A.P., Vaccaro A.R., Hall J.A., Whang P.G., Friel B.C., McKee M.D. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int. Orthop. 2007, 31:735-741.
51. McKay W.F., Peckham S.M., Badura J.M. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft). Int. Orthop. 2007, 31:729-734.
52. Garrison K.R., Shemilt I., Donell S., Ryder J.J., Mugford M., Harvey I., Song F., Alt V. Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst. Rev. 2010, CD006950.
53. Brandoff J.F., Silber J.S., Vaccaro A.R. Contemporary alternatives to synthetic bone grafts for spine surgery. Am. J. Orthop. (Belle Mead N.J.) 2008, 37:410-414.
54. Lan J., Wang Z.F., Shi B., Xia H.B., Cheng X.R. The influence of recombinant human BMP-2 on bone-implant osseointegration: biomechanical testing and histomorphometric analysis. Int. J. Oral Maxillofac. Surg. 2007, 36:345-349.
55. Luo T., Zhang W., Shi B., Cheng X., Zhang Y. Enhanced bone regeneration around dental implant with bone morphogenetic protein 2 gene and vascular endothelial growth factor protein delivery. Clin. Oral Implants Res. 2012, 23:467-473.
56. Sanders D., Swiontkowski M.F. The critical sized defect in the tibia: Is it critical? Results from the SPRINT trial. Abstract of 2011 Annual Meeting of the American Academy of Orthopaedic Surgeons Podium No: 382 2011.
57. Govender S., et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J. Bone Joint Surg. Am. 2002, 84-A:2123-2134.
58. Swiontkowski M.F., et al. Recombinant human bone morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J. Bone Joint Surg. Am. 2006, 88:1258-1265.
59. (April 30, 2004). United States Food and Drug Administration, Department of Health and Human Services, Center for Devices and Radiological Health. INFUSE Bone Graft - P000054. http://www.accessdata.fda.gov/cdrh_docs/pdf/P000054a.pdf.
60. Alt V., Donell S.T., Chhabra A., Bentley A., Eicher A., Schnettler R. A health economic analysis of the use of rhBMP-2 in Gustilo-Anderson grade III open tibial fractures for the UK, Germany, and France. Injury 2009, 40:1269-1275.
61. Aro H.T., et al. Recombinant human bone morphogenetic protein-2: a randomized trial in open tibial fractures treated with reamed nail fixation. J. Bone Joint Surg. Am. 2011, 93:801-808.
62. A Randomized Controlled Cost Study of Infuse BMP 2 vs Iliac Crest Autograft for Non Union of Long Bone Fractures. ClinicalTrials.gov, Bethesda, MD 15 September 2011, Capital District Health Authority, Canada, http://www.clinicaltrials.gov/ct2/show/NCT00856479.
63. Tibial Delayed Healing Pivotal Clinical Trial, Medtronic Spinal and Biologicals. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://clinicaltrials.gov/ct2/show/NCT01016067.
64. rhBMP-2 Versus Autograft in Critical Size Tibial Defects, Major Extremity Trauma Research Consortia. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://clinicaltrials.gov/ct2/show/NCT00853489.
65. Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures, Wyeth-a Wholly Owned Subsidiary of Pfizer. ClinicalTrials.gov, Bethesda, MD, 15 September 2011 15 September 2011, http://clinicaltrials.gov/ct2/show/NCT00161629.
66. A Study of rhBMP-2/CPM in Closed Fractures of the Humerus, Wyeth-a Wholly Owned Subsidiary of Pfizer. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://clinicaltrials.gov/ct2/show/NCT00384852.
67. Feasibility and Safety Study of rhBMP-2/CPM for Hip Fractures, Wyeth-a Wholly Owned Subsidiary of Pfizer. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://clinicaltrials.gov/ct2/show/NCT00384358.
68. A Phase 2/3 Multicenter, Controlled Trial of rhBMP-2/CPM in Tibial Fractures, Pfizer Subsidiary-Wyeth. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://clinicaltrials.gov/ct2/show/NCT00387686.
69. A Phase 2, Multicenter, Double-blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) as an Adjuvant Therapy in Closed Fractures of the Humerus, Pfizer, Inc. ClinicalStudyResults.org 15 September 2011, http://www.clinicalstudyresults.org/documents/company-study_11378_0.pdf.
70. 15. A Phase 2, Multicenter, Singleblind, Randomized, Stratified, Standard-or-Care Controlled, Feasibility and Safety Study of rhBMP-2/CPM as an Adjuvant Therapy for Fractures of the Proximal Femur, Pfizer, Inc. ClinicalStudyResults.org 15 September 2011, http://www.clinicalstudyresults.org/documents/company-study_11402_0.pdf.
71. Friedlaender G.E., et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J. Bone Joint Surg. Am. 2001, 83-A(Suppl. 1):S151-S158.
72. Geesink R.G., Hoefnagels N.H., Bulstra S.K. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J. Bone Joint Surg. Br. 1999, 81:710-718.
73. Bong M.R., Capla E.L., Egol K.A., Sorkin A.T., Distefano M., Buckle R., Chandler R.W., Koval K.J. Osteogenic protein-1 (bone morphogenic protein-7) combined with various adjuncts in the treatment of humeral diaphyseal nonunions. Bull. Hosp. Jt. Dis. 2005, 63:20-23.
74. Ristiniemi J., Flinkkila T., Hyvonen P., Lakovaara M., Pakarinen H., Jalovaara P. RhBMP-7 accelerates the healing in distal tibial fractures treated by external fixation. J. Bone Joint Surg. Br. 2007, 89:265-272.
75. Calori G.M., Tagliabue L., Gala L., d'Imporzano M., Peretti G., Albisetti W. Application of rhBMP-7 and platelet-rich plasma in the treatment of long bone non-unions: a prospective randomised clinical study on 120 patients. Injury 2008, 39:1391-1402.
76. Dahabreh Z., Calori G.M., Kanakaris N.K., Nikolaou V.S., Giannoudis P.V. A cost analysis of treatment of tibial fracture nonunion by bone grafting or bone morphogenetic protein-7. Int. Orthop. 2009, 33:1407-1414.
77. OP Device vs. Bone Autograft for the Treatment of Tibial Nonunions, Olympus Biotech Corporation. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://www.clinicaltrials.gov/ct2/show/NCT00679328.
78. A Prospective Randomized Controlled Trial on the Use of Bone Morphogenetic 7 (BMP-7) (OP-1) and Demineralized Bone Matrix in Tibial Non-Union, University Hospital, Ghent. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://www.clinicaltrials.gov/ct2/show/NCT00551941.
79. Schwartz C.E., Martha J.F., Kowalski P., Wang D.A., Bode R., Li L., Kim D.H. Prospective evaluation of chronic pain associated with posterior autologous iliac crest bone graft harvest and its effect on postoperative outcome. Health Qual. Life Outcomes 2009, 7:49.
80. Burkus J.K., Transfeldt E.E., Kitchel S.H., Watkins R.G., Balderston R.A. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 2002, 27:2396-2408.
81. Baskin D.S., Ryan P., Sonntag V., Westmark R., Widmayer M.A. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine (Phila Pa 1976) 2003, 28:1219-1224. (discussion 1225).
82. Burkus J.K., Sandhu H.S., Gornet M.F., Longley M.C. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J. Bone Joint Surg. Am. 2005, 87:1205-1212.
83. Glassman S.D., Carreon L., Djurasovic M., Campbell M.J., Puno R.M., Johnson J.R., Dimar J.R. Posterolateral lumbar spine fusion with INFUSE bone graft. Spine J. 2007, 7:44-49.
84. Glassman S.D., Carreon L.Y., Djurasovic M., Campbell M.J., Puno R.M., Johnson J.R., Dimar J.R. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion: a randomized, controlled trial in patients over sixty years of age. Spine (Phila Pa 1976) 2008, 33:2843-2849.
85. Carreon L.Y., Glassman S.D., Djurasovic M., Campbell M.J., Puno R.M., Johnson J.R., Dimar J.R. RhBMP-2 versus iliac crest bone graft for lumbar spine fusion in patients over 60 years of age: a cost-utility study. Spine (Phila Pa 1976) 2009, 34:238-243.
86. 32. Spine Fusion Instrumented with BMP-2 vs Uninstrumented with Infuse BMP-2 Alone, Capital District Health Authority, Canada. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://www.clinicaltrials.gov/ct2/show/NCT00405600.
87. Boden S.D., Kang J., Sandhu H., Heller J.G. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 2002, 27:2662-2673.
88. Glassman S.D., Dimar J.R., Carreon L.Y., Campbell M.J., Puno R.M., Johnson J.R. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion. Spine (Phila Pa 1976) 2005, 30:1694-1698.
89. Dimar J.R., Glassman S.D., Burkus K.J., Carreon L.Y. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine (Phila Pa 1976) 2006, 31:2534-2539. (discussion 2540).
90. Mulconrey D.S., Bridwell K.H., Flynn J., Cronen G.A., Rose P.S. Bone morphogenetic protein (RhBMP-2) as a substitute for iliac crest bone graft in multilevel adult spinal deformity surgery: minimum two-year evaluation of fusion. Spine (Phila Pa 1976) 2008, 33:2153-2159.
91. Dawson E., Bae H.W., Burkus J.K., Stambough J.L., Glassman S.D. Recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge with an osteoconductive bulking agent in posterolateral arthrodesis with instrumentation. A prospective randomized trial. J. Bone Joint Surg. Am. 2009, 91:1604-1613.
92. Lanman T.H., Hopkins T.J. Lumbar interbody fusion after treatment with recombinant human bone morphogenetic protein-2 added to poly(L-lactide-co-D, L-lactide) bioresorbable implants. Neurosurg. Focus. 2004, 16:E9.
93. Katayama Y., et al. Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average five-year follow-up study. Int. Orthop. 2009, 33:1061-1067.
94. Boakye M., Mummaneni P.V., Garrett M., Rodts G., Haid R. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J. Neurosurg. Spine 2005, 2:521-525.
95. Meisel H.J., Schnoring M., Hohaus C., Minkus Y., Beier A., Ganey T., Mansmann U. Posterior lumbar interbody fusion using rhBMP-2. Eur. Spine J. 2008, 17:1735-1744.
96. rhBMP-2/CRM/CD HORIZON Spinal System Pivotal Study, Medtronic Spinal and Biologics. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://clinicaltrials.gov/ct2/show/NCT00707265.
97. Johnsson R., Stromqvist B., Aspenberg P. Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 2002, 27:2654-2661.
98. Vaccaro A.R., et al. A pilot safety and efficacy study of OP-1 putty (rhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur. Spine J. 2003, 12:495-500.
99. Vaccaro A.R., et al. A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine (Phila Pa 1976) 2004, 29:1885-1892.
100. Vaccaro A.R., et al. A 2-year follow-up pilot study evaluating the safety and efficacy of op-1 putty (rhbmp-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur. Spine J. 2005, 14:623-629.
101. Vaccaro A.R., et al. Comparison of OP-1 Putty (rhBMP-7) to iliac crest autograft for posterolateral lumbar arthrodesis: a minimum 2-year follow-up pilot study. Spine (Phila Pa 1976) 2005, 30:2709-2716.
102. Furlan J.C., Perrin R.G., Govender P.V., Petrenko Y., Massicotte E.M., Rampersaud Y.R., Lewis S., Fehlings M.G. Use of osteogenic protein-1 in patients at high risk for spinal pseudarthrosis: a prospective cohort study assessing safety, health-related quality of life, and radiographic fusion. Invited submission from the Joint Section on Disorders of the Spine and Peripheral Nerves, March 2007. J. Neurosurg. Spine 2007, 7:486-495.
103. Leach J., Bittar R.G. BMP-7 (OP-1) safety in anterior cervical fusion surgery. J. Clin. Neurosci. 2009, 16:1417-1420.
104. 54. A Prospective Pilot Study of the OP-1 Putty in Uninstrumented Posterolateral Fusions, Olympus Biotech Corporation. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://www.clinicaltrials.gov/ct2/show/NCT00679107.
105. OP-1 Putty for Posterolateral Fusions, Olympus Biotech Corporation. ClincalTrials.gov, Bethesda, MD 15 September 2011, http://www.clinicaltrials.gov/ct2/show/NCT00677950.
106. Study of OP-1 Putty in Uninstrumented Posterolateral Fusions, Olympus Biotech Corporation. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://www.clinicaltrials.gov/ct2/show/NCT00678353.
107. A Pilot Study to Evaluate an OP-1 Putty Spinal System and an Autograft Spinal System, Olympus Biotech Corporation. ClinicalTrials.gov, Bethesda, MD 15 September 2011, http://www.clinicaltrials.gov/ct2/show/NCT00678171.
108. Vaidya R., Sethi A., Bartol S., Jacobson M., Coe C., Craig J.G. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions. J. Spinal Disord. Tech. 2008, 21:557-562.
109. Smucker J.D., Rhee J.M., Singh K., Yoon S.T., Heller J.G. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976) 2006, 31:2813-2819.
110. Smoljanovic T., Bojanic I., Delimar D. Adverse effects of posterior lumbar interbody fusion using rhBMP-2. Eur. Spine J. 2009, 18:920-923. (author reply 924).
111. Carragee E.J., Hurwitz E.L., Weiner B.K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011, 11:471-491.
112. Yilmaz S., Kilic A.R., Keles A., Efeoglu E. Reconstruction of an alveolar cleft for orthodontic tooth movement. Am. J. Orthod. Dentofacial Orthop. 2000, 117:156-163.
113. Tasoulis G., Yao S.G., Fine J.B. The maxillary sinus: challenges and treatments for implant placement. Compend. Contin. Educ. Dent. 2011, 32:10-14. (16, 18-9; quiz 20, 34).
114. Sittitavornwong S., Gutta R. Bone graft harvesting from regional sites. Oral. Maxillofac. Surg. Clin. North Am. 2010, 22:317-330. v-vi.
115. Wikesjo U.M., Qahash M., Huang Y.H., Xiropaidis A., Polimeni G., Susin C. Bone morphogenetic proteins for periodontal and alveolar indications; biological observations-clinical implications. Orthod. Craniofac. Res. 2009, 12:263-270.
116. Boyne P.J., Marx R.E., Nevins M., Triplett G., Lazaro E., Lilly L.C., Alder M., Nummikoski P. A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Int. J. Periodontics Restorative Dent. 1997, 17:11-25.
117. Garg A. Bone morphogenetic protein (BMP) for sinus lift. Dent. Implantol. Update 2010, 21:25-29.
118. Triplett R.G., Nevins M., Marx R.E., Spagnoli D.B., Oates T.W., Moy P.K., Boyne P.J. Pivotal, randomized, parallel evaluation of recombinant human bone morphogenetic protein-2/absorbable collagen sponge and autogenous bone graft for maxillary sinus floor augmentation. J. Oral Maxillofac. Surg. 2009, 67:1947-1960.
119. Cochran D.L., Jones A.A., Lilly L.C., Fiorellini J.P., Howell H. Evaluation of recombinant human bone morphogenetic protein-2 in oral applications including the use of endosseous implants: 3-year results of a pilot study in humans. J. Periodontol. 2000, 71:1241-1257.
120. Boerckel J.D., Kolambkar Y.M., Dupont K.M., Uhrig B.A., Phelps E.A., Stevens H.Y., Garcia A.J., Guldberg R.E. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials 2011, 32:5241-5251.
121. Giteau A., Venier-Julienne M.C., Aubert-Pouëssel A., Benoit J.P. How to achieve sustained and complete protein release from PLGA-based microparticles?. Int. J. Pharm. 2008, 350:14-26.
122. Dahabreh Z., Dimitriou R., Giannoudis P.V. Health economics: a cost analysis of treatment of persistent fracture non-unions using bone morphogenetic protein-7. Injury 2007, 38:371-377.
123. Zhang H., Sucato D.J., Welch R.D. Recombinant human bone morphogenic protein-2-enhanced anterior spine fusion without bone encroachment into the spinal canal: a histomorphometric study in a thoracoscopically instrumented porcine model. Spine (Phila Pa 1976) 2005, 30:512-518.
124. Lee M., Li W., Siu R.K., Whang J., Zhang X., Soo C., Ting K., Wu B.M. Biomimetic apatite-coated alginate/chitosan microparticles as osteogenic protein carriers. Biomaterials 2009, 30:6094-6101.
125. Sato K., Miura T., Iwata H. Cartilaginous transdifferentiation of rat tenosynovial cells under the influence of bone morphogenetic protein in tissue culture. Clin. Orthop. Relat. Res. 1988, 233-239.
126. Vargha R., Endemann M., Kratochwill K., Riesenhuber A., Wick N., Krachler A.M., Malaga-Dieguez L., Aufricht C. Ex vivo reversal of in vivo transdifferentiation in mesothelial cells grown from peritoneal dialysate effluents. Nephrol. Dial. Transplant. 2006, 21:2943-2947.
127. Bessa P.C., Casal M., Reis R.L. Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J. Tissue Eng. Regen. Med. 2008, 2:81-96.
128. Kempen D.H., Lu L., Hefferan T.E., Creemers L.B., Maran A., Classic K.L., Dhert W.J., Yaszemski M.J. Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. Biomaterials 2008, 29:3245-3252.
129. Geiger M., Li R.H., Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv. Drug Deliv. Rev. 2003, 55:1613-1629.
130. Hecht B.P., Fischgrund J.S., Herkowitz H.N., Penman L., Toth J.M., Shirkhoda A. The use of recombinant human bone morphogenetic protein 2 (rhBMP-2) to promote spinal fusion in a human primate anterior interbody fusion model. Spine (Phila Pa 1976) 1999, 24:629-636.
131. Itoh H., Ebara S., Kamimura M., Tateiwa Y., Kinoshita T., Yuzawa Y., Takaoka K. Experimental spinal fusion with use of recombinant human bone morphogenetic protein 2. Spine (Phila Pa 1976) 1999, 24:1402-1405.
132. David S.M., Gruber H.E., Meyer R.A., Murakami T., Tabor O.B., Howard B.A., Wozney J.M., Hanley E.N. Lumbar spinal fusion using recombinant human bone morphogenetic protein in the canine. A comparison of three dosages and two carriers. Spine (Phila Pa 1976) 1999, 24:1973-1979.
133. Barnes B., Boden S.D., Louis-Ugbo J., Tomak P.R., Park J.S., Park M.S., Minamide A. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates. Spine (Phila Pa 1976) 2005, 30:1127-1133.
134. Tan K.J., Liao S., Chan C.K. Controlled release of recombinant human bone morphogenetic protein-7 in nanoscaffolds. Nanomedicine (Lond) 2007, 2:385-390.
135. Liu Y., Hunziker E.B., Van de Vaal C., de Groot K. Biomimetic Coatings vs. Collagen Sponges as a Carrier for BMP-2: A Comparison of the Osteogenic Responses Triggered In Vivo Using an Ectopic Rat Model. Key Eng. Mater. 2004, 254-256:619-622.
136. Yamamoto M., Takahashi Y., Tabata Y. Enhanced bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein-2 from a biodegradable hydrogel. Tissue Eng. 2006, 12:1305-1311.
137. Hunt D.R., Jovanovic S.A., Wikesjö U.M., Wozney J.M., Bernard G.W. Hyaluronan supports recombinant human bone morphogenetic protein-2 induced bone reconstruction of advanced alveolar ridge defects in dogs. A pilot study. J. Periodontol. 2001, 72:651-658.
138. Eckardt H., Christensen K.S., Lind M., Hansen E.S., Hall D.W.R., Hvid I. Recombinant human bone morphogenetic protein 2 enhances bone healing in an experimental model of fractures at risk of non-union. Injury 2005, 36:489-494.
139. Kim J., et al. Bone regeneration using hyaluronic acid-based hydrogel with bone morphogenic protein-2 and human mesenchymal stem cells. Biomaterials 2007, 28:1830-1837.
140. Patterson J., Siew R., Herring S.W., Lin A.S., Guldberg R., Stayton P.S. Hyaluronic acid hydrogels with controlled degradation properties for oriented bone regeneration. Biomaterials 2010, 31:6772-6781.
141. Martinez-Sanz E., Ossipov D.A., Hilborn J., Larsson S., Jonsson K.B., Varghese O.P. Bone reservoir: Injectable hyaluronic acid hydrogel for minimal invasive bone augmentation. J. Control. Release 2011, 152:232-240.
142. Bergman K., Engstrand T., Hilborn J., Ossipov D., Piskounova S., Bowden T. Injectable cell-free template for bone-tissue formation. J. Biomed. Mater. Res. A 2009, 91:1111-1118.
143. Fragonas E., Valente M., Pozzi-Mucelli M., Toffanin R., Rizzo R., Silvestri F., Vittur F. Articular cartilage repair in rabbits by using suspensions of allogenic chondrocytes in alginate. Biomaterials 2000, 21:795-801.
144. Simmons C.A., Alsberg E., Hsiong S., Kim W.J., Mooney D.J. Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone 2004, 35:562-569.
145. Fu T.S., Chen W.J., Chen L.H., Lin S.S., Kiu S.J., Ueng S.W. Enhancement of posterolateral lumbar spine fusion using low-dose rhBMP-2 and cultured marrow stromal cells. J. Orthop. Res. 2009, 27:380-384.
146. Kolambkar Y.M., Dupont K.M., Boerckel J.D., Huebsch N., Mooney D.J., Hutmacher D.W., Guldberg R.E. An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 2011, 32:65-74.
147. Tan R., She Z., Wang M., Yu X., Jin H., Feng Q. Repair of rat calvarial bone defects by controlled release of rhBMP-2 from an injectable bone regeneration composite. J. Tissue Eng. Regen. Med. 2012, 6:614-621.
148. Abarrategi A., Civantos A., Ramos V., Sanz Casado J.V., López-Lacomba J.L. Chitosan film as rhBMP2 carrier: delivery properties for bone tissue application. Biomacromolecules 2008, 9:711-718.
149. Abarrategi A., Moreno-Vicente C., Ramos V., Aranaz I., Sanz Casado J.V., Lopez-Lacomba J.L. Improvement of porous beta-TCP scaffolds with rhBMP-2 chitosan carrier film for bone tissue application. Tissue Eng. Part A 2008, 14:1305-1319.
150. Zhao J., et al. Enhanced healing of rat calvarial defects with sulfated chitosan coated CDHA/BMP-2 scaffolds. Tissue Eng. Part A 2012, 18:185-197.
151. Stephan S.J., Tholpady S.S., Gross B., Petrie-Aronin C.E., Botchway E.A., Nair L.S., Ogle R.C., Park S.S. Injectable tissue-engineered bone repair of a rat calvarial defect. Laryngoscope 2010, 120:895-901.
152. Luca L., Rougemont A.L., Walpoth B.H., Boure L., Tami A., Anderson J.M., Jordan O., Gurny R. Injectable rhBMP-2-loaded chitosan hydrogel composite: osteoinduction at ectopic site and in segmental long bone defect. J. Biomed. Mater. Res. A 2011, 96:66-74.
153. Engstrand T., Veltheim R., Arnander C., Docherty-Skogh A.C., Westermark A., Ohlsson C., Adolfsson L., Larm O. A novel biodegradable delivery system for bone morphogenetic protein-2. Plast. Reconstr. Surg. 2008, 121:1920-1928.
154. Karageorgiou V., Meinel L., Hofmann S., Malhotra A., Volloch V., Kaplan D. Bone morphogenetic protein-2 decorated silk fibroin films induce osteogenic differentiation of human bone marrow stromal cells. J. Biomed. Mater. Res. A 2004, 71:528-537.
155. Karageorgiou V., et al. Porous silk fibroin 3-D scaffolds for delivery of bone morphogenetic protein-2 in vitro and in vivo. J. Biomed. Mater. Res. A 2006, 78:324-334.
156. Bessa P.C., et al. Silk fibroin microparticles as carriers for delivery of human recombinant bone morphogenetic protein-2: in vitro and in vivo bioactivity. Tissue Eng. Part C Methods 2010, 16:937-945.
157. Zhang W., et al. The use of injectable sonication-induced silk hydrogel for VEGF(165) and BMP-2 delivery for elevation of the maxillary sinus floor. Biomaterials 2011, 32:9415-9224.
158. Murphy G., Gavrilovic J. Proteolysis and cell migration: creating a path?. Curr. Opin. Cell Biol. 1999, 11:614-621.
159. Patel V.V., Zhao L., Wong P., Pradhan B.B., Bae H.W., Kanim L., Delamarter R.B. An in vitro and in vivo analysis of fibrin glue use to control bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth. Spine J. 2006, 6:397-403. (discussion 404).
160. Chung Y.I., Ahn K.M., Jeon S.H., Lee S.Y., Lee J.H., Tae G. Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. J. Control. Release 2007, 121:91-99.
161. Yang H.S., La W.G., Bhang S.H., Jeon J.Y., Lee J.H., Kim B.S. Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Eng. Part A 2010, 16:1225-1233.
162. Keibl C., Fugl A., Zanoni G., Tangl S., Wolbank S., Redl H., van Griensven M. Human adipose derived stem cells reduce callus volume upon BMP-2 administration in bone regeneration. Injury 2011, 42:814-820.
163. Tay B.K., Patel V.V., Bradford D.S. Calcium sulfate- and calcium phosphate-based bone substitutes. Mimicry of the mineral phase of bone. Orthop. Clin. North Am. 1999, 30:615-623.
164. El-Ghannam A. Bone reconstruction: from bioceramics to tissue engineering. Expert Rev. Med. Devices 2005, 2:87-101.
165. Dorozhkin S.V. Bioceramics of calcium orthophosphates. Biomaterials 2010, 31:1465-1485.
166. Noshi T., et al. Recombinant human bone morphogenetic protein-2 potentiates the in vivo osteogenic ability of marrow/hydroxyapatite composites. Artif. Organs 2001, 25:201-208.
167. Morisue H., et al. A novel hydroxyapatite fiber mesh as a carrier for recombinant human bone morphogenetic protein-2 enhances bone union in rat posterolateral fusion model. Spine (Phila Pa 1976) 2006, 31:1194-1200.
168. Zhu W., et al. Experimental study of nano-hydroxyapatite/recombinant human bone morphogenetic protein-2 composite artificial bone. Artif. Cells Blood Substit. Immobil. Biotechnol. 2010, 38:150-156.
169. Blattert T.R., Delling G., Dalal P.S., Toth C.A., Balling H., Weckbach A. Successful transpedicular lumbar interbody fusion by means of a composite of osteogenic protein-1 (rhBMP-7) and hydroxyapatite carrier: a comparison with autograft and hydroxyapatite in the sheep spine. Spine (Phila Pa 1976) 2002, 27:2697-2705.
170. Ripamonti U., Crooks J., Rueger D.C. Induction of bone formation by recombinant human osteogenic protein-1 and sintered porous hydroxyapatite in adult primates. Plast. Reconstr. Surg. 2001, 107:977-988.
171. Tazaki J., Murata M., Akazawa T., Yamamoto M., Ito K., Arisue M., Shibata T., Tabata Y. BMP-2 release and dose-response studies in hydroxyapatite and beta-tricalcium phosphate. Biomed. Mater. Eng. 2009, 19:141-146.
172. Bucholz R.W., Carlton A., Holmes R.E. Hydroxyapatite and tricalcium phosphate bone graft substitutes. Orthop. Clin. North Am. 1987, 18:323-334.
173. Ohyama T., Kubo Y., Iwata H., Taki W. Beta-tricalcium phosphate combined with recombinant human bone morphogenetic protein-2: a substitute for autograft, used for packing interbody fusion cages in the canine lumbar spine. Neurol. Med. Chir. (Tokyo) 2004, 44:234-240.
174. Maus U., Andereya S., Gravius S., Ohnsorge J.A., Niedhart C., Siebert C.H. BMP-2 incorporated in a tricalcium phosphate bone substitute enhances bone remodeling in sheep. J. Biomater. Appl. 2008, 22:559-576.
175. Luvizuto E.R., Tangl S., Zanoni G., Okamoto T., Sonoda C.K., Gruber R., Okamoto R. The effect of BMP-2 on the osteoconductive properties of β-tricalcium phosphate in rat calvaria defects. Biomaterials 2011, 32:3855-3861.
176. Fellah B.H., Gauthier O., Weiss P., Chappard D., Layrolle P. Osteogenicity of biphasic calcium phosphate ceramics and bone autograft in a goat model. Biomaterials 2008, 29:1177-1188.
177. Alam M.I., Asahina I., Ohmamiuda K., Takahashi K., Yokota S., Enomoto S. Evaluation of ceramics composed of different hydroxyapatite to tricalcium phosphate ratios as carriers for rhBMP-2. Biomaterials 2001, 22:1643-1651.
178. Boden S.D., Martin G.J., Morone M.A., Ugbo J.L., Moskovitz P.A. Posterolateral lumbar intertransverse process spine arthrodesis with recombinant human bone morphogenetic protein 2/hydroxyapatite-tricalcium phosphate after laminectomy in the nonhuman primate. Spine (Phila Pa 1976) 1999, 24:1179-1185.
179. Jang J.W., Yun J.H., Lee K.I., Jang J.W., Jung U.W., Kim C.S., Choi S.H., Cho K.S. Osteoinductive activity of biphasic calcium phosphate with different rhBMP-2 doses in rats. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2012, 113:480-487.
180. Majid K., Tseng M.D., Baker K.C., Reyes-Trocchia A., Herkowitz H.N. Biomimetic calcium phosphate coatings as bone morphogenetic protein delivery systems in spinal fusion. Spine J. 2011, 11:560-567.
181. Louis-Ugbo J., et al. Retention of 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J. Orthop. Res. 2002, 20:1050-1059.
182. Suh D.Y., Boden S.D., Louis-Ugbo J., Mayr M., Murakami H., Kim H.S., Minamide A., Hutton W.C. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate. Spine (Phila Pa 1976) 2002, 27:353-360.
183. Akamaru T., Suh D., Boden S.D., Kim H.S., Minamide A., Louis-Ugbo J. Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion. Spine (Phila Pa 1976) 2003, 28:429-434.
184. Takaoka K., Nakahara H., Yoshikawa H., Masuhara K., Tsuda T., Ono K. Ectopic bone induction on and in porous hydroxyapatite combined with collagen and bone morphogenetic protein. Clin. Orthop. Relat. Res. 1988, 250-254.
185. Itoh S., et al. The biocompatibility and osteoconductive activity of a novel hydroxyapatite/collagen composite biomaterial, and its function as a carrier of rhBMP-2. J. Biomed. Mater. Res. 2001, 54:445-453.
186. Itoh S., Kikuchi M., Takakuda K., Nagaoka K., Koyama Y., Tanaka J., Shinomiya K. Implantation study of a novel hydroxyapatite/collagen (HAp/col) composite into weight-bearing sites of dogs. J. Biomed. Mater. Res. 2002, 63:507-515.
187. Sun T.S., Guan K., Shi S.S., Zhu B., Zheng Y.J., Cui F.Z., Zhang W., Liao S.S. Effect of nano-hydroxyapatite/collagen composite and bone morphogenetic protein-2 on lumbar intertransverse fusion in rabbits. Chin. J. Traumatol. 2004, 7:18-24.
188. Matsumoto G., Omi Y., Kubota E., Ozono S., Tsuzuki H., Kinoshita Y., Yamamoto M., Tabata Y. Enhanced regeneration of critical bone defects using a biodegradable gelatin sponge and beta-tricalcium phosphate with bone morphogenetic protein-2. J. Biomater. Appl. 2009, 24:327-342.
189. Liu Y., et al. Segmental bone regeneration using an rhBMP-2-loaded gelatin/nanohydroxyapatite/fibrin scaffold in a rabbit model. Biomaterials 2009, 30:6276-6285.
190. Gu Y., Chen L., Yang H.L., Luo Z.P., Tang T.S. Evaluation of an injectable silk fibroin enhanced calcium phosphate cement loaded with human recombinant bone morphogenetic protein-2 in ovine lumbar interbody fusion. J. Biomed. Mater. Res. A 2011, 97:177-185.
191. Saito N., Takaoka K. New synthetic biodegradable polymers as BMP carriers for bone tissue engineering. Biomaterials 2003, 24:2287-2293.
192. Saito N., et al. Synthetic biodegradable polymers as drug delivery systems for bone morphogenetic proteins. Adv. Drug Deliv. Rev. 2005, 57:1037-1048.
193. Miyamoto S., Takaoka K., Okada T., Yoshikawa H., Hashimoto J., Suzuki S., Ono K. Evaluation of polylactic acid homopolymers as carriers for bone morphogenetic protein. Clin. Orthop. Relat. Res. 1992, 274-285.
194. Miyamoto S., Takaoka K., Okada T., Yoshikawa H., Hashimoto J., Suzuki S., Ono K. Polylactic acid-polyethylene glycol block copolymer. A new biodegradable synthetic carrier for bone morphogenetic protein. Clin. Orthop. Relat. Res. 1993, 333-343.
195. Saito N., Okada T., Toba S., Miyamoto S., Takaoka K. New synthetic absorbable polymers as BMP carriers: plastic properties of poly-D, L-lactic acid-polyethylene glycol block copolymers. J. Biomed. Mater. Res. 1999, 47:104-110.
196. Saito N., et al. Biodegradable poly-d,l-lactic acid-polyethylene glycol block copolymers as a BMP delivery system for inducing bone. J. Bone Joint Surg. Am. 2001, 83-A(Suppl. 1):S92-S98.
197. Saito N., et al. A biodegradable polymer as a cytokine delivery system for inducing bone formation. Nat. Biotechnol. 2001, 19:332-335.
198. Suzuki A., Terai H., Toyoda H., Namikawa T., Yokota Y., Tsunoda T., Takaoka K. A biodegradable delivery system for antibiotics and recombinant human bone morphogenetic protein-2: a potential treatment for infected bone defects. J. Orthop. Res. 2006, 24:327-332.
199. Takahashi J., Saito N., Ebara S., Kinoshita T., Itoh H., Okada T., Nozaki K., Takaoka K. Anterior thoracic spinal fusion in dogs by injection of recombinant human bone morphogenetic protein-2 and a synthetic polymer. J. Spinal Disord. Tech. 2003, 16:137-143.
200. Sandhu H.S., Kanim L.E., Kabo J.M., Toth J.M., Zeegen E.N., Liu D., Delamarter R.B., Dawson E.G. Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Spine (Phila Pa 1976) 1996, 21:2115-2122.
201. Kandziora F., et al. Bone morphogenetic protein-2 application by a poly(D, L-lactide)-coated interbody cage: in vivo results of a new carrier for growth factors. J. Neurosurg. 2002, 97:40-48.
202. Yoneda M., Terai H., Imai Y., Okada T., Nozaki K., Inoue H., Miyamoto S., Takaoka K. Repair of an intercalated long bone defect with a synthetic biodegradable bone-inducing implant. Biomaterials 2005, 26:5145-5152.
203. Murakami N., et al. Repair of a proximal femoral bone defect in dogs using a porous surfaced prosthesis in combination with recombinant BMP-2 and a synthetic polymer carrier. Biomaterials 2003, 24:2153-2159.
204. Liao S.S., Guan K., Cui F.Z., Shi S.S., Sun T.S. Lumbar spinal fusion with a mineralized collagen matrix and rhBMP-2 in a rabbit model. Spine (Phila Pa 1976) 2003, 28:1954-1960.
205. Namikawa T., et al. Experimental spinal fusion with recombinant human bone morphogenetic protein-2 delivered by a synthetic polymer and beta-tricalcium phosphate in a rabbit model. Spine (Phila Pa 1976) 2005, 30:1717-1722.
206. Eguchi Y., Wakitani S., Imai Y., Naka Y., Hashimoto Y., Nakamura H., Takaoka K. Antitumor necrotic factor agent promotes BMP-2-induced ectopic bone formation. J. Bone Miner. Metab. 2010, 28:157-164.
207. Park E.J., Kim E.S., Weber H.P., Wright R.F., Mooney D.J. Improved bone healing by angiogenic factor-enriched platelet-rich plasma and its synergistic enhancement by bone morphogenetic protein-2. Int. J. Oral Maxillofac. Implants 2008, 23:818-826.
208. Facca S., Ferrand A., Mendoza-Palomares C., Perrin-Schmitt F., Netter P., Mainard D., Liverneaux P., Benkirane-Jessel N. Bone formation induced by growth factors embedded into the nanostructured particles. J. Biomed. Nanotechnol. 2011, 7:482-485.
209. Isobe M., Yamazaki Y., Oida S., Ishihara K., Nakabayashi N., Amagasa T. Bone morphogenetic protein encapsulated with a biodegradable and biocompatible polymer. J. Biomed. Mater. Res. 1996, 32:433-438.
210. Woo B.H., et al. Enhancement of bone growth by sustained delivery of recombinant human bone morphogenetic protein-2 in a polymeric matrix. Pharm. Res. 2001, 18:1747-1753.
211. Weber F.E., Eyrich G., Gratz K.W., Maly F.E., Sailer H.F. Slow and continuous application of human recombinant bone morphogenetic protein via biodegradable poly(lactide-co-glycolide) foamspheres. Int. J. Oral Maxillofac. Surg. 2002, 31:60-65.
212. Bessho K., Carnes D.L., Cavin R., Ong J.L. Experimental studies on bone induction using low-molecular-weight poly (dl-lactide-co-glycolide) as a carrier for recombinant human bone morphogenetic protein-2. J. Biomed. Mater. Res. 2002, 61:61-65.
213. Fu Y.C., Nie H., Ho M.L., Wang C.K., Wang C.H. Optimized bone regeneration based on sustained release from three-dimensional fibrous PLGA/HAp composite scaffolds loaded with BMP-2. Biotechnol. Bioeng. 2008, 99:996-1006.
214. Kang J.M., Kang S.W., La W.G., Yang Y.S., Kim B.S. Enhancement of in vivo bone regeneration efficacy of osteogenically undifferentiated human cord blood mesenchymal stem cells. J. Biomed. Mater. Res. A 2010, 93:666-672.
215. Wei G., Jin Q., Giannobile W.V., Ma P.X. The enhancement of osteogenesis by nano-fibrous scaffolds incorporating rhBMP-7 nanospheres. Biomaterials 2007, 28:2087-2096.
216. Liu H., Webster T.J. Ceramic/polymer nanocomposites with tunable drug delivery capability at specific disease sites. J. Biomed. Mater. Res. A 2010, 93:1180-1192.
217. Ruhe P.Q., Boerman O.C., Russel F.G., Spauwen P.H., Mikos A.G., Jansen J.A. Controlled release of rhBMP-2 loaded poly(dl-lactic-co-glycolic acid)/calcium phosphate cement composites in vivo. J. Control. Release 2005, 106:162-171.
218. Kim S.S., Gwak S.J., Kim B.S. Orthotopic bone formation by implantation of apatite-coated poly(lactide-co-glycolide)/hydroxyapatite composite particulates and bone morphogenetic protein-2. J. Biomed. Mater. Res. A 2008, 87:245-253.
219. Choi D.H., Park C.H., Kim I.H., Chun H.J., Park K., Han D.K. Fabrication of core-shell microcapsules using PLGA and alginate for dual growth factor delivery system. J. Control. Release 2010, 147:193-201.
220. Oest M.E., Dupont K.M., Kong H.J., Mooney D.J., Guldberg R.E. Quantitative assessment of scaffold and growth factor-mediated repair of critically sized bone defects. J. Orthop. Res. 2007, 25:941-950.
221. Ji Y., Xu G.P., Zhang Z.P., Xia J.J., Yan J.L., Pan S.H. BMP-2/PLGA delayed-release microspheres composite graft, selection of bone particulate diameters, and prevention of aseptic inflammation for bone tissue engineering. Ann. Biomed. Eng. 2010, 38:632-639.
222. Liu H.W., Chen C.H., Tsai C.L., Lin I.H., Hsiue G.H. Heterobifunctional poly(ethylene glycol)-tethered bone morphogenetic protein-2-stimulated bone marrow mesenchymal stromal cell differentiation and osteogenesis. Tissue Eng. 2007, 13:1113-1124.
223. Kempen D.H., Kruyt M.C., Lu L., Wilson C.E., Florschutz A.V., Creemers L.B., Yaszemski M.J., Dhert W.J. Effect of autologous bone marrow stromal cell seeding and bone morphogenetic protein-2 delivery on ectopic bone formation in a microsphere/poly(propylene fumarate) composite. Tissue Eng. Part A 2009, 15:587-594.
224. Kempen D.H., Lu L., Heijink A., Hefferan T.E., Creemers L.B., Maran A., Yaszemski M.J., Dhert W.J. Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration. Biomaterials 2009, 30:2816-2825.
225. Jeon O., Song S.J., Kang S.W., Putnam A.J., Kim B.S. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(l-lactic-co-glycolic acid) scaffold. Biomaterials 2007, 28:2763-2771.
226. Kang S.W., La W.G., Kang J.M., Park J.H., Kim B.S. Bone morphogenetic protein-2 enhances bone regeneration mediated by transplantation of osteogenically undifferentiated bone marrow-derived mesenchymal stem cells. Biotechnol. Lett. 2008, 30:1163-1168.
227. Kim S.E., Jeon O., Lee J.B., Bae M.S., Chun H.J., Moon S.H., Kwon I.K. Enhancement of ectopic bone formation by bone morphogenetic protein-2 delivery using heparin-conjugated PLGA nanoparticles with transplantation of bone marrow-derived mesenchymal stem cells. J. Biomed. Sci. 2008, 15:771-777.
228. La W.G., Kang S.W., Yang H.S., Bhang S.H., Lee S.H., Park J.H., Kim B.S. The efficacy of bone morphogenetic protein-2 depends on its mode of delivery. Artif. Organs 2010, 34:1150-1153.
229. Nair L.S., Laurencin C.T. Biodegradable polymers as biomaterials. Prog. Polym. Sci. 2007, 32:762-798.
230. Sawyer A.A., Song S.J., Susanto E., Chuan P., Lam C.X., Woodruff M.A., Hutmacher D.W., Cool S.M. The stimulation of healing within a rat calvarial defect by mPCL-TCP/collagen scaffolds loaded with rhBMP-2. Biomaterials 2009, 30:2479-2488.
231. Johnson M.R., Boerckel J.D., Dupont K.M., Guldberg R.E. Functional restoration of critically sized segmental defects with bone morphogenetic protein-2 and heparin treatment. Clin. Orthop. Relat. Res. 2011, 469:3111-3117.
232. Bae J.H., Song H.R., Kim H.J., Lim H.C., Park J.H., Liu Y., Teoh S.H. Discontinuous release of bone morphogenetic protein-2 loaded within interconnected pores of honeycomb-like polycaprolactone scaffold promotes bone healing in a large bone defect of rabbit ulna. Tissue Eng. Part A 2011, 17:2389-2397.
233. Abbah S.A., Lam C.X., Ramruttun A.K., Goh J.C., Wong H.K. Fusion Performance of Low Dose rhBMP-2 and BMSCs in Biodegradable Scaffolds: A Comparative Study in a Large Animal Model of Anterior Lumbar Interbody Fusion. Spine (Phila Pa 1976) 2011, 36:1752-1759.
234. FDA Public Health Notification: Life-threatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion Retrieved from. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/PublicHealthNotifications/ucm062000.htm.
235. Woo E.J. Expanded indication for recombinant human bone morphogenetic protein 2. Spine (Phila Pa 1976) 2011, 36:1817. (author reply 1817-8).
236. Meier B., Wilson D. Spine Experts Repudiate Medtronic Studies. The New York Times March 21 2012, http://www.nytimes.com/2011/06/29/business/29spine.html.
237. New infuse scandal could hit medtronic hard, analyst says 2011, News Inferno, http://www.newsinferno.com/defective-medical-devices/new-infuse-scandal-could-hit-medtronic-hard-analyst-says/32089.
238. Infuse lawsuits pile up for Medtronic MassDevice http://www.massdevice.com/news/infuse-lawsuits-pile-medtronic-legal-news.
239. More Medtronic Shareholders Head to Court in Lawsuit Over Infuse Marketing 2012, News Inferno, http://www.newsinferno.com/defective-medical-devices/more-medtronic-shareholders-head-to-court-in-lawsuit-over-infuse-marketing/36225.
240. Senators introduce bi-partisan medical device bill. Mass Device 2012, http://www.massdevice.com/news/senators-introduce-bi-partisan-medical-device-bill.
241. Gamradt S.C., Lieberman J.R. Genetic modification of stem cells to enhance bone repair. Ann. Biomed. Eng. 2004, 32:136-147.
242. Mroz T.E., Wang J.C., Hashimoto R., Norvell D.C. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 2010, 35:S86-S104.
243. Mundy G., et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
244. Sugiyama M., Kodama T., Konishi K., Abe K., Asami S., Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem. Biophys. Res. Commun. 2000, 271:688-692.
245. Gutierrez G., Garrett I.R., Rossini G.e.a. Dermal application of lovastatin to rats causes greater increases in bone formation and plasma concentrations that when administered by oral gavage. J. Bone Miner. Res. 2000, 15:S427.
246. Whang K., Zhao M., Qiao M., Rossini G., Horn D., Garrett I.R., Mundy G.R., Chen D. Administration of lovastatin locally in low doses in a novel delivery system induces prolonged bone formation. J. Bone Miner. Res. 2000, 15:S225.
247. Maeda T., Matsunuma A., Kawane T., Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 2001, 280:874-877.
248. Garrett I.R., Gutierrez G., Mundy G.R. Statins and bone formation. Curr. Pharm. Des. 2001, 7:715-736.
249. Maritz F.J., Conradie M.M., Hulley P.A., Gopal R., Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1636-1641.
250. Edwards C.J., Spector T.D. Statins as modulators of bone formation. Arthritis Res. 2002, 4:151-153.
251. Chen P.Y., Sun J.S., Tsuang Y.H., Chen M.H., Weng P.W., Lin F.H. Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr. Res. 2010, 30:191-199.
252. Eichler K., Puhan M.A., Bachmann L.M. The role of statins in primary prevention of cardiovascular disease. Arch. Intern. Med. 2007, 167:1100. (author reply 1100-1).
253. Cushenberry L., Debittner M.R. Potential use of HMG-CoA reductase inhibitors for osteoporosis. Ann. Pharmacother. 2002, 36:671-678.
254. Zhao J., Ohba S., Shinkai M., Chung U.I., Nagamune T. Icariin induces osteogenic differentiation in vitro in a BMP- and Runx2-dependent manner. Biochem. Biophys. Res. Commun. 2008, 369:444-448.
255. Zhao J., Ohba S., Komiyama Y., Shinkai M., Chung U.I., Nagamune T. Icariin: a potential osteoinductive compound for bone tissue engineering. Tissue Eng. Part A 2010, 16:233-243.
256. Wei H., Zili L., Yuanlu C., Biao Y., Cheng L., Xiaoxia W., Yang L., Xing W. Effect of icariin on bone formation during distraction osteogenesis in the rabbit mandible. Int. J. Oral Maxillofac. Surg. 2011, 40:413-418.
257. Yoshikawa T., Nakajima H., Yamada E., Akahane M., Dohi Y., Ohgushi H., Tamai S., Ichijima K. In vivo osteogeneic capability of cultured allogeneic bone in porous hydroxvapatite: immunosuppressive and osteogeneic potential of FK506 in vivo. J. Bone Miner. Res. 2000, 15:1147-1157.
258. Voggenreiter G., Assenmacher S., Kreuzfelder E., Wolf M., Kim M.R., Nast-Kolb D., Schade F.U. Immunosuppression with FK506 increases bone induction in demineralized isogeneic and xenogeneic bone matrix in the rat. J. Bone Miner. Res. 2000, 15:1825-1834.
259. Tang L., Ebara S., Kawasaki S., Wakabayashi S., Nikaido T., Takaoka K. FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol. Int. 2002, 26:75-84.
260. Kugimiya F., Yano F., Ohba S., Igawa K., Nakamura K., Kawaguchi H., Chung U.I. Mechanism of osteogenic induction by FK506 via BMP/Smad pathways. Biochem. Biophys. Res. Commun. 2005, 338:872-879.
261. Yoshikawa T., Nakajima H., Uemura T., Kasai T., Enomoto Y., Tamura T., Nonomura A., Takakura Y. In vitro bone formation induced by immunosuppressive agent tacrolimus hydrate (FK506). Tissue Eng. 2005, 11:609-617.
262. Ogawa T., Tokuda M., Tomizawa K., Matsui H., Itano T., Konishi R., Nagahata S., Hatase O. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast like osteosarcoma (ROS 17/2.8) cells. Biochem. Biophys. Res. Commun. 1998, 249:226-230.
263. Lee K.W., Yook J.Y., Son M.Y., Kim M.J., Koo D.B., Han Y.M., Cho Y.S. Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. Stem Cells Dev. 2010, 19:557-568.
264. Ohba S., et al. A novel osteogenic helioxanthin-derivative acts in a BMP-dependent manner. Biochem. Biophys. Res. Commun. 2007, 357:854-860.
265. Park K.W., Waki H., Kim W.K., Davies B.S., Young S.G., Parhami F., Tontonoz P. The small molecule phenamil induces osteoblast differentiation and mineralization. Mol. Cell. Biol. 2009, 29:3905-3914.
266. Lo K.W.-H., Kan H.M., Ashe K.M., Laurencin C.T. The small molecule PKA-selective cyclic AMP analogue as an inducer of osteoblast-like cells differentiation and mineralization. J. Tissue Eng. Regen. Med. 2011, Epub a head of print. 10.1002/term.395.
267. Yuan H., et al. Osteoinductive ceramics as a synthetic alternative to autologous bone grafting. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13614-13619.